Efficacy of matrix regenerating agent in improving wound healing and pain relief in a patient undergoing transepithelial photorefractive laser treatment

Session Details

Session Title: SMILE vs PRK, Ocular Surface Disease

Session Date/Time: Monday 24/09/2018 | 08:00-10:30

Paper Time: 09:40

Venue: Room A3, Podium 3

First Author: : J.Gertnere LATVIA

Co Author(s): :    I. Solomatins   J. Mescheryakova   A. Solomatin   M. Solomatin           

Abstract Details

Purpose:

To report prospective case control study with the use of matrix regenerating agent (RGTA) Cacicol® after transepithelial PRK to assess the epithelial healing and pain.

Setting:

Dr. Solomatin Eye Center Riga

Methods:

44 eyeas (22 patients) were selected to this prospective double blended study. All the eyes underwent transepithelial PRK.The RGTA Cacicol® eye drops were installed once in the right eye of every patient immediately after the laser surgery. Placebo eye drops were used for the left eye. The bandage CL were placed to cover the erosions for 3days. Patients were assessed at 24, 48 and 72 hours postop. Using Visual Analog Scale was subjectively assessed the postoperative pain. Epithelial defect area size was measured manually using Pentacam corneal density map with millimeter ruler and special formula of the wrong oval area.

Results:

In first 24 h after surgery the pain score was 4.4in Cacicol group and 4.1 in control group, but epithelial defect area was 427.4 mm² and 441.5 mm². In the next postoperative day (48h) the pain score was 4.6in Cacicol group and 4.3 in control group, but epithelial defect area was 234.3mm² and 259.5 mm². In third postoperative day (72h) the pain score was 4.1in Cacicol group and 3.9 in control group, but epithelial defect area was 41.6mm² and 60.4mm².

Conclusions:

Analysis of data with repeated measures ANOVA test showed that use of RGTA Cacicol did not show statistically faster recovery and the changes in erosion (p=0.971) or in subjective reported pain score (p=0.999). In all case groups, there were no adverse events and incidents of inflammation or delayed healing after transepithelial PRK.

Financial Disclosure:

... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented